Arbutus Biopharma
ABUS
48 hedge funds and large institutions have $100M invested in Arbutus Biopharma in 2014 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 6 increasing their positions, 18 reducing their positions, and 12 closing their positions.
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
23% more funds holding
Funds holding: 39 → 48 (+9)
3% more capital invested
Capital invested by funds: $97.6M → $100M (+$2.77M)
38% less call options, than puts
Call options by funds: $13.5M | Put options by funds: $21.7M
67% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$6.82M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.52M |
| 3 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$2.89M |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$1.63M |
| 5 |
U
UBS
Zurich,
Switzerland
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$20M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$12.8M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$9.23M |
| 4 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
-$4.83M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$3.13M |
ABUS Hedge Fund Activity: Q3 2014 in Review
48 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2014, worth a combined $100M — up 2.8% from $97.6M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ABUS positions and 12 closed out — a net gain of 9 holders — while 6 added to existing stakes and 18 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $6.82M. The largest seller was Franklin Resources, cutting an estimated $20M.
- 48 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2014, up from 39 in Q2 2014.
- Funds reported $100M of Arbutus Biopharma stock for Q3 2014, up 2.8% quarter-over-quarter.
- 21 funds opened new Arbutus Biopharma positions in Q3 2014 and 12 closed out, a net change of +9 holders.
- The largest Arbutus Biopharma buyer in Q3 2014 was Morgan Stanley, an estimated $6.82M added.
- The largest Arbutus Biopharma seller in Q3 2014 was Franklin Resources, an estimated $20M sold.
Based on aggregated 13F filings for Q3 2014.